- Press Releases
- Notices
Press Releases To List
-
- Mar.09.2026Sustainability
- Ono Pharma Selected as "2026 Health & Productivity Stock"
-
- Mar.05.2026Management / Finance
- Notice Concerning Disposal of Treasury Shares by Third-Party Allotment
-
- Mar.05.2026Corporate
- Notice concerning Introduction of Long-Term Incentive Stock Plan for Employees of Deciphera, the U.S. Subsidiary
-
- Mar.03.2026Licensing
- Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
-
- Mar.02.2026Products
- Ono Pharma Announces Transfer of the Manufacturing and Marketing Approval Authorization for Opalmon® Tablets and Prostandin® Ointment to Daito Pharmaceutical Co., Ltd.
Notices To List
-
- Feb.04.2026Corporate
- Notice about Posting of the Financial Result Meeting for FY2025 Q3 - Script
-
- Jan.15.2026Corporate
- The 44th Annual J.P. Morgan Healthcare Conference Presentation Materials Posted
-
- Nov.04.2025Corporate
- Notice about Posting of the Financial Result Meeting for FY2025 Q2 - Script
-
- Sep.29.2025Corporate
- Corporate Report 2025 has been released.
-
- Aug.04.2025Corporate
- Notice about Posting of the Financial Result Meeting for FY2025 Q1 - Script
About
We Want to Deliver New Drugs
to the World with a Wish.
For more than 300 years since its foundation in 1717, working for people’s health.
Diseases still unconquered. Patients' wishes still unfulfilled.
ONO, with a wish to meet these medical needs, devotes all its efforts to drug discovery.
